Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

✍ Scribed by Valero, V.; Forbes, J.; Pegram, M. D.; Pienkowski, T.; Eiermann, W.; von Minckwitz, G.; Roche, H.; Martin, M.; Crown, J.; Mackey, J. R.; Fumoleau, P.; Rolski, J.; Mrsic-Krmpotic, Z.; Jagiello-Gruszfeld, A.; Riva, A.; Buyse, M.; Taupin, H.; Sauter, G.; Press, M. F.; Slamon, D. J.

• Book ID: 125851628
• Publisher: American Society of Clinical Oncology
• Year: 2011
• Tongue: English
• Weight: 257 KB
• Volume: 29
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/JCO.2010.28.6450